Corbus Pharmaceuticals Holding (CRBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Corbus Pharmaceuticals Holding (CRBP) has a cash flow conversion efficiency ratio of -0.290x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.63 Million) by net assets ($102.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CRBP market cap overview for the company's overall valuation and market capitalisation.
Corbus Pharmaceuticals Holding - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Corbus Pharmaceuticals Holding's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Corbus Pharmaceuticals Holding Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corbus Pharmaceuticals Holding ranked by their cash flow conversion efficiency. Explore CRBP cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Tongtech Co Ltd
SHE:300379
|
-0.012x |
|
Caribou Biosciences Inc
NASDAQ:CRBU
|
-0.232x |
|
Impiana Hotels Bhd
KLSE:7243
|
-0.111x |
|
Korea Information Certificate Authority Inc
KQ:053300
|
0.019x |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
N/A |
|
OPTIMIZERx Corp
NASDAQ:OPRX
|
0.026x |
|
Acusensus Ltd
AU:ACE
|
0.023x |
|
Hooker Furniture Corporation
NASDAQ:HOFT
|
0.085x |
Annual Cash Flow Conversion Efficiency for Corbus Pharmaceuticals Holding (2012–2025)
The table below shows the annual cash flow conversion efficiency of Corbus Pharmaceuticals Holding from 2012 to 2025. View CRBP stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $147.50 Million | $-64.49 Million | -0.437x | -49.00% |
| 2024-12-31 | $142.43 Million | $-41.79 Million | -0.293x | -100.01% |
| 2023-12-31 | $-6.91 Million | $-36.10 Billion | 5228.164x | +459494.91% |
| 2022-12-31 | $32.99 Million | $-37.54 Million | -1.138x | -63.23% |
| 2021-12-31 | $69.11 Million | $-48.18 Million | -0.697x | +68.33% |
| 2020-12-31 | $45.27 Million | $-99.69 Million | -2.202x | +70.35% |
| 2019-12-31 | $6.16 Million | $-45.72 Million | -7.425x | -579.71% |
| 2018-12-31 | $27.52 Million | $-30.07 Million | -1.092x | -127.09% |
| 2017-12-31 | $57.78 Million | $-27.80 Million | -0.481x | +68.38% |
| 2016-12-31 | $8.92 Million | $-13.57 Million | -1.522x | -194.17% |
| 2015-12-31 | $8.99 Million | $-4.65 Million | -0.517x | -28.43% |
| 2014-12-31 | $5.86 Million | $-2.36 Million | -0.403x | -295.84% |
| 2013-12-31 | $-1.78 Million | $-366.71K | 0.206x | -94.70% |
| 2012-12-31 | $-198.38 | $-769.73 | 3.880x | -- |
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treat… Read more